GYN
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Induction Chemo Followed by CRT in Advanced Cervical Cancer - QoL Outcomes From GCIG INTERLACE
FEATURING
Gemma Eminowicz
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant Chemo +/- RT in Pts With Newly Diagnosed, High-Risk Endometrial Cancer From ENGOT-EN11/GOG-3053/KEYNOTE-B21
FEATURING
Brian Slomovitz
- 9 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS from the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo with Standard Cx + Bev in Ovarian Cancer Patients with Platinum-Sensitive Relapse
FEATURING
Jean-Emmanuel Kurtz
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Clinical and Molecular Predictors of Outcome in Patients With Tubo-Ovarian High-Grade Serous Carcinoma and Exceptional Survival
FEATURING
Tibor A. Zwimpfer
- 11 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 39 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 98 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: OS Results for Pembro + CRT for High-Risk Locally Advanced Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18
FEATURING
Domenica Lorusso
- 64 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial
FEATURING
Bradley J. Monk
- 153 views
- September 19, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Advanced Ovarian Cancer - PRIMA Trial
FEATURING
Bradley J. Monk
- 153 views
- September 19, 2024
- 1